OWCP - OWC Pharmaceutical Research Corp.
| Previous Close | 0.250 |
| Open | 0.250 |
| Bid | 0.000 x 0 |
| Ask | 0.000 x 0 |
| Day's Range | 0.240 - 0.255 |
| 52 Week Range | 0.200 - 1.140 |
| Volume | 235,213 |
| Avg. Volume | 1,081,561 |
| Market Cap | 36.14M |
| Beta | -10.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.033 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire•last month
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders. In the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the "Company"). The Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients' lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.
- PR Newswire•2 months ago
OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer
RAMAT GAN, Israel, Feb. 20, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO). Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry.
- The Wall Street Journal•2 months ago
Corrections & Amplifications
Corrections & Amplifications for the edition of Feb. 5, 2018.
- PR Newswire•3 months ago
OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference
OWC Pharmaceutical Research Corp. [OWC Pharma](OWCP) is pleased to announce it will be a Diamond Sponsor at the 2018 Wall Street Conference. This is second consecutive year OWC Pharma will be attending this prestigious investment conference to be held on February 21st , 2018 at the Hilton Doubletree Hotel & Convention Center in Boca Raton, Florida. The Wall Street Conference is one of the premiere conferences in the venture capital arena and Small Cap marketplace.
- PR Newswire•4 months ago
OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet
PETACH TIKVA, Israel, Dec. 21, 2017 /PRNewswire/ -- In December 2017, OWC Pharmaceutical Research Corp (OWCP) received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. In October of 2016 OWC announced that it had completed the development of a proprietary cannabinoid-enriched sublingual tablet (the "Tablet") for the administration of medical cannabis.
- PR Newswire•7 months ago
OWC Pharma Issues Chairman's Letter to Shareholders
OWC Pharma (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders. Following my recent appointment as Chairman at OWC Pharma (OWCP), it is my pleasure to introduce myself to you and to initiate a new tradition of biannual shareholder update letters.
- PR Newswire•9 months ago
OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman
OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Stanley Hirsch as its active chairman of the board of directors. Dr. Stanley Hirsch, age 59, has had extensive scientific, executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.
- Marketwired•9 months ago
CFN Media Exclusive Interview with OWCP's Dr. Sharon Rozenblat
CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview with Dr. Sharon Rozenblat, Advisory Board ...
- PR Newswire•9 months ago
OWC Pharmaceutical Research Takes Further Actions to Protect its Intellectual Property
OWC Pharmaceutical Research Corp. (OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the European Union Patent and Trademark Office for its active cannabinoid-based psoriasis topical cream.
- PR Newswire•10 months ago
OWC Pharmaceutical Research Corp. Announces Market Readiness of its Cannabinoid-based Topical Cream for Skin Conditions Starting With Psoriasis
OWC Pharmaceutical Research Corp. (OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the United States Patent and Trademark Office for its active cannabinoid-based topical cream. This new patent application follows the previously filed 'provisional' patent application.
- Marketwired•10 months ago
OWC Pharmaceuticals Engages CFN Media to Cultivate New Investor Audience & Communicate with Existing Shareholders
CFN Media Group , the leading agency and digital media network dedicated to the North American cannabis industry, today announced that OWC Pharmaceutical Research Corp. has engaged CFN Media to conduct ...
- PR Newswire•11 months ago
OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts
OWC Pharmaceutical Research Corp. (OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market. Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets.
- PR Newswire•last year
OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study
OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. ("OWC") has determined the road map for continuing the Multiple Myeloma study.